ClinicalTrials.gg
RecruitingNCT05577364Updated Dec 14, 2023

Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients

A Phase 1/2 interventional study of Selinexor and R-CHOP Protocol in EBV-Positive Diffuse Large B-Cell Lymphoma, Nos, sponsored by Sun Yat-sen University. Recruiting at 2 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-12-14.

Sponsored by Sun Yat-sen University · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Nov 2022; still recruiting 4 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
54
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This is a prospective, single-arm, multi-center, phase Ib/II clinical trial to evaluate the safety, tolerability, and efficacy of selinexor in combination with R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone) followed by selinexor maintenance for untreated EBV-positive diffuse large B-cell lymphoma (DLBCL) patients.

Read the detailed description

This is a prospective, single-arm, multi-center, phase Ib/II clinical trial to explore the maximum tolerated dose (MTD) of selinexor when combined with R-CHOP regimen for untreated EBV-positive DLBCL patients.

Phase Ib study:

Selinexor will be given orally at two different doses (40mg qw, and 60mg qw ) and combined with the R-CHOP regimen from the second cycle based on the "3+3" principle.

In the induction therapy period, 6 cycles of R-CHOP regimen and 2 cycles of rituximab in combination with selinexor are planned.

The dose limited toxicity (DLT) will be evaluated after the first cycle of selinexor in combination with R-CHOP.

Phase II study:

The phase II study of selinexor at recommended phase II dose (RP2D) dose level combined with R-CHOP regimen was conducted to explore the efficacy and safety of the combined regimen.

After 8 cycles of induction therapy, if the response is assessed as complete remission (CR), maintenance therapy with selinexor will be conducted.

02

Conditions studied

  • EBV-Positive Diffuse Large B-Cell Lymphoma, Nos

Keywords

  • untreated, EBV-positive diffuse large B-cell lymphoma
03

In context

Lead sponsor

Sun Yat-sen University is the lead sponsor of 1,695 studies on the registry; 622 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects fully understand and voluntarily participate in this study and sign
  2. Age ≥18, ≤70 years, no gender limitation.
  3. confirmed diagnosis of EBV-positive diffuse large B-cell lymphoma (DLBCL) (more than 50% of tumor cells are positive with EBV encoded small RNAs (EBERs) in situ hybridization were considered EBERs positive).
  4. Untreated patients, except for the short-time use of prednisone for controlling tumor-induced symptoms (no more than 30mg/d (or other equivalent amounts of other ), no more than 7 days).
  5. There must be at least one measurable or evaluable lesion that meets the evaluation criteria for Lugano 2014 lymphoma: : Positron emission tomography/computed tomography (PET/CT) or CT and/or MRI, intranodal lesions with long diameter >1.5cm, and short diameter >1.0cm, or extranodal lesions with long diameter > 1.0 cm.
  6. (ECOG) Performance Status (PS) 0-2.
  7. Expected survival ≥ 3 months.
  8. Adequate function of bone marrow:

    White blood cell ≥3.0×10E9/L, ≥1.5×10E9/L ≥100×10E9/L (Bone marrow invasive patient≥75×109/L) ≥ 90g/L No granulocyte growth factor, platelet, or red blood cell transfusions were received within 14 days prior to examination.

  9. Adequate function of the liver and renal:

    Total ≤2× (ULN) (patients with liver invasion or Gilbert syndrome ≤5×ULN) (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN (patients with liver invasion ≤5×ULN) Serum creatinine ≤1.5×ULN or rate ≥60 mL/min

  10. The patients agree to take effective measures during the study period and till 12 months after the last administration of the study treatment.

Exclusion criteria

Exclusion Criteria:

  1. EBV-positive DLBCL combined with other types of lymphoma. Transformed DLBCL.
  2. EBV-positive DLBCL with central nervous system invasion.
  3. The patients had previously received XPO1 inhibitors, such as selinexor and so on.
  4. The patients have to any drug in the combined treatment.
  5. The major surgery is performed within 4 weeks before enrollment, except for diagnosis.
  6. There are any life-threatening diseases, medical conditions or organ system dysfunction that the investigator believes may affect the safety or compliance of patients.
  7. Heart function and disease meet one of the following conditions:

    1. Heart failure with the classification of heart function of grade II;
    2. A history of unstable angina pectoris;
    3. A history of myocardial infarction within the past 1 years;
    4. Patients with supraventricular or ventricular arrhythmia requiring treatment or intervention;
  8. A history of other malignant tumors within the past 5 years (except the cured cervical cancer and basal cell carcinoma of the skin).
  9. Patients with active bleeding.
  10. Uncontrolled infection exists within 7 days before treatment and parenteral antibiotics, antiviral drugs or antifungal drugs are needed; However, preventive use of these drugs (including parenteral anti-infective drugs) is allowed.
  11. Patients with chronic active or active . If the background hepatitis B Surface Antigen (HBsAg) and/or hepatitis B core Antibody (HBcAb) or hepatitis C Virus (HCV) antibody are positive, the further determination for Hepatitis B Virus (HBV) DNA (no more than 2500 copies /mL or 500 IU/mL) and HCV RNA (no more than the lower limit of the assay) can be included. The patients with HBsAg and/or HBcAb positive need to receive anti-HBV drugs.
  12. Patients with the infection of (HIV) and/or acquired Immunodeficiency syndrome.
  13. Inability to swallow tablets, presence of malabsorption syndrome, or any other gastrointestinal disease or dysfunction that may affect the absorption of the study drug.
  14. Pregnant and lactating women, and subjects of childbearing age who do not want to use .
  15. Mentally ill persons or persons unable to obtain .
  16. The investigators think that the patient is not suitable for the study.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
54 participants (estimated)

Study arms

  • Experimental
    Selinexor in Combination With R-CHOP

    Patients with untreated EBV-positive diffuse large B-cell lymphoma will receive sequentially higher doses of selinexor in combination with R-CHOP regimen from the second cycle of R-CHOP (3 weeks per cycle).The initial dose of selinexor is 40mg qw po. After 8 cycles of induction therapy, if the response is assessed as complete remission (CR), maintenance therapy with selinexor will be conducted.

    Drug: Selinexor · Drug: R-CHOP Protocol

Interventions

  • Selinexor: 40mg qw po, and 60mg qw po (phase Ib); RP2D (II study); Selinexor is added from the second cycle of R-CHOP regimen.

    Also known as: exportin 1 (XPO1) inhibitor

  • Rituximab: 375mg/m2 iv.drip D1; Cyclophosphamide: 750mg/m2 iv.drip D1; Doxorubicin: 50mg/m2 iv.drip D1; Vincristine: 1.4g/m2 iv D1; Prednisone: 100mg po D1-5;

    Also known as: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone

06

What researchers measure

Primary outcomes

  1. Maximum tolerated dose (MTD)

    To identify the MDT

    Time frame: The first cycle of selinexor in combination with R-CHOP regimen (21 days)

  2. Recommended Phase II Dose (RP2D)

    To identify the RP2D

    Time frame: The first cycle of selinexor in combination with R-CHOP regimen (21 days)

  3. Complete response rate (CRR)

    To investigate the preliminary antitumor efficacy

    Time frame: Up to 24 weeks.

Secondary outcomes

  1. Disease-free survival (DFS)

    To investigate the preliminary antitumor efficacy

    Time frame: From date of the first complete response until the date of the first documented progression or date of death from any cause, whichever came first, assessed up to 24 months

  2. Objective response rate (ORR)

    To investigate the preliminary antitumor efficacy

    Time frame: Up to 24 weeks.

  3. Progression-free survival (PFS)

    To investigate the preliminary antitumor efficacy

    Time frame: From date of the first injection until the date of the first documented progression or date of death from any cause, whichever came first, assessed up to 24 months

  4. Overall survival (OS)

    To investigate the preliminary antitumor efficacy

    Time frame: From date of the first injection until the date of death from ant cause, assessed up to 24 months

  5. Number of participants with adverse events (AE) and severe adverse events (SAE) as assessed by CTCAE v5.0

    To identify the incidence of AE and SAE

    Time frame: Through study completion, an average of 2 years.

Other outcomes

  1. The correlation between EBV-DNA level and efficacy indicators, such as CRR, DFS, ORR, PFS, and OS

    To explore the correlation between EBV-DNA level and response

    Time frame: Through study completion, an average of 2 years.

  2. The gene mutations such as DDX3X、TET2、PTPN2 and so on are sequenced by whole genome sequencing.

    To explore the correlations between gene mutations and response and prognosis.

    Time frame: Through study completion, an average of 2 years.

  3. The mRNA and lncRNA alterations are sequenced by transcriptome sequencing.

    To explore the correlations between RNA alterations and response and prognosis.

    Time frame: Through study completion, an average of 2 years.

  4. Immune-related indicators such as LAG-3, PD-1, PD-L1, TIGIF, CTLA-4, and so on are assessed by immunohistochemical (IHC) staining.

    To explore the correlations between immune-related indicators and response and prognosis.

    Time frame: Through study completion, an average of 2 years.

07

Study locations

2 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2022 (actual). Primary completion is estimated for Dec 2024, 25 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2022
First posted
Oct 13, 2022
StartActual
Nov 1, 2022
Primary completionEst.
Dec 31, 2024
CompletionEst.
Feb 28, 2026
Last update
Dec 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05577364
Collaborators
Fudan University, Antengene Corporation
Responsible party
Qingqing Cai (chief physician, Sun Yat-sen University) — Principal investigator
First posted
Oct 13, 2022
Start date
Nov 1, 2022
Primary completion
Dec 31, 2024 (estimated)
Completion
Feb 28, 2026 (estimated)
Last update
Dec 14, 2023

Study contacts

Qingqing Cai, MD. PhD.
Contact
caiqq@sysucc.org.cn
0086-20-87342823
Huiqiang Huang, MD. PhD.
Contact
huanghq@sysucc.org.cn
0086-20-87342823

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selinexor

Start the discussion